Method for preparing beta-nicotinamide mononucleotide by enzyme method

Through the multi-enzyme cascade reaction system, ATP cycle regeneration and AMP recovery system, the problems of large amount of enzyme consumption and PRPP hydrolysis in enzymatic synthesis of NMN are solved, and low-cost and efficient production is achieved, with the NMN yield reaching more than 90%.

CN119061094AInactive Publication Date: 2024-12-03DALIAN UNIV OF TECH

Patent Information

Application Number
CN202411352527.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-26
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing enzyme method for synthesis of β-nicotinamide single nucleotide (NMN) consumes a lot of enzymes and costs high, and the intermediate product phosphoribose pyrophosphate (PRPP) is easy to hydrolyze, resulting in low NMN yield, expensive market price and limited source , limiting low-cost and efficient production.

Method used

Using a multi-enzyme cascade reaction system, including ribokinase, phosphoribophosphate kinase, nicotinamide phosphoribose transferase, polyphosphate kinase, AMP nucleosidase and pyrophosphate hydrolase, ATP cycle regeneration and AMP recovery systems, through Polyphosphate achieves PRPP synthesis, reducing enzyme dosage and intermediate product investment.

Benefits of technology

It significantly reduces the proportion of enzyme consumption to production costs, improves NMN yield, and achieves low-cost and efficient synthesis. The NMN yield can reach more than 90%, avoiding the synthesis pathway of increasing PRPP under the conditions of additional feeding.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119061094A_ABST
    Figure CN119061094A_ABST
Patent Text Reader

Abstract

The invention discloses a method for preparing beta-nicotinamide mononucleotide by an enzyme method, and belongs to the technical field of biology. According to the method, D-ribose, nicotinamide and adenosine triphosphate ATP are used as raw materials, ribose kinase, phosphoribose pyrophosphokinase and nicotinamide phosphoribose transferase are used for catalytic synthesis of NMN, polyphosphokinase and polyphosphate are introduced into a reaction system to form regeneration cycle of ATP, pyrophosphohydrolase is introduced to hydrolyze PPi, and the NMN is obtained by hydrolysis of PPi. The adverse effect of byproducts ADP and PPi on the yield is eliminated while the cyclic utilization of ATP is ensured; an AMP recovery system is constructed by using AMP nucleosidase, a byproduct AMP is converted into ribose 5 phosphate, and then the ribose 5 phosphate is converted into PRPP, so that the synthetic route of the PRPP is increased under the condition of no additional feeding, and the NMN synthetic efficiency is further improved. The yield of the finally obtained NMN reaches 90% or above, and efficient synthesis of the NMN under the low-enzyme-amount condition is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology and relates to a method for generating nicotinamide mononucleotide by enzymatic catalysis, in particular to a method for preparing β-nicotinamide mononucleotide by enzymatic method. Background Art

[0002] β-Nicotinamide mononucleotide (NMN) is a biochemical substance existing in biological cells. After adenylation by β-nicotinamide nucleotide adenylyltransferase, it is converted into nicotinamide adenine dinucleotide (NAD, also known as coenzyme I), an important substance for cell survival. It is also directly involved in the transfer of adenosine in the body. Its level in biological cells directly affects the concentration of NAD, plays an important role in the energy generation of biological cells, and is harmless to the human body.

[0003] Up to now, people have discovered that NMN has many medical and health care functions, such as delaying aging, treating Parkinson's and other geriatric diseases, regulating insulin secretion, and affecting mRNA expression. More uses are still under development. With the increasing awareness of the medicinal and health effects of NMN, and its widespread application as a reaction substrate in chemical industry, the market demand for NMN is increasing day by day.

[0004] At present, the preparation methods of NMN mainly include the following three methods: 1. Chemical synthesis method, 2. Microbial fermentation method, 3. Bio-enzyme catalysis method. Among them, the chemical method has too many impurities in the production process, pollutes the environment, and is easy to generate chiral isomers, resulting in high synthesis costs and is not easy to produce on a large scale. The microbial fermentation method mainly uses enzyme engineering and metabolic engineering to transform engineered bacteria to construct NMN high-yield strains. However, due to its own reasons, the product of the fermentation method is very easy to be consumed and utilized by the bacteria themselves, affecting the production of NMN. Therefore, the demand for selecting the enzyme method for efficient synthesis of NMN is gradually increasing.

[0005] Enzymatic synthesis of NMN mainly uses cheap and readily available substances as starting substrates and is synthesized by multi-enzyme cascade reactions. Among them, due to the low cost of ribose, it is usually used as the preferred starting substrate for enzymatic synthesis of NMN. However, in the current enzymatic synthesis of NMN pathway, the amount of enzyme consumed is large, and the enzyme substrate molar ratio of the enzyme used reaches more than 1:1000, among which the enzyme substrate molar ratio of the key enzyme nicotinamide phosphoribosyltransferase (Nampt) reaches more than 1:100. In order to obtain a higher yield of NMN, a large amount of enzyme must be used. However, the greater the amount of enzyme used, the higher the proportion of enzyme cost in NMN production. Therefore, in order to promote industrial-scale production and achieve efficient and low-cost synthesis of NMN, it is necessary to reduce the amount of enzyme used in the multi-enzyme cascade reaction of NMN synthesis. In addition, in the current cascade reaction of synthesizing NMN with ribose as the starting substrate, the intermediate product ribose pyrophosphate (PRPP) is easily hydrolyzed, which makes it difficult to increase the yield of NMN. The market price of PRPP is expensive and the source is limited. Exogenous input of PRPP or additional feed supplementation will incur higher costs, limiting the low-cost and efficient production of NMN. Therefore, it is necessary to develop a new method for the efficient synthesis of NMN with low enzyme consumption, which can also make up for the loss caused by the hydrolysis of the intermediate product PRPP, so as to reduce the industrial production cost of NMN. Summary of the invention

[0006] In view of the shortcomings of the prior art, the present invention provides a method for enzymatically synthesizing β-nicotinamide mononucleotide, which uses D-ribose, nicotinamide and adenine nucleoside triphosphate ATP as raw materials, prepares NMN in a one-pot process under the coupled catalysis of ribokinase Rbk, phosphoribosyl pyrophosphokinase Prs and nicotinamide phosphoribosyltransferase Nampt, and simultaneously introduces polyphosphate kinase PPK2Ⅱ and polyphosphate PolyP to realize the cyclic regeneration of ATP, utilizes pyrophosphate hydrolase PPase to eliminate the influence of pyrophosphate PPi on the yield, and utilizes AMP nucleosidase Amn to recover the byproduct adenine nucleoside monophosphate AMP in the system, converts it into 5-phosphate ribose R-5-P, and then converts it into phosphoribosyl pyrophosphate PRPP, thereby increasing the synthesis pathway of PRPP without additional feeding, and producing NMN with low cost and high efficiency.

[0007] To achieve the above object, the present invention provides the following technical solutions:

[0008] The invention provides a method for preparing beta-nicotinamide mononucleotide by an enzymatic method. The method uses polyphosphate, nicotinamide, D-ribose and ATP as substrates, synthesizes beta-nicotinamide mononucleotide NMN under the catalytic action of a multi-enzyme system of ribokinase Rbk, phosphoribosyl pyrophosphokinase Prs, nicotinamide phosphoribosyltransferase Nampt, polyphosphate kinase PPK2Ⅱ, AMP nucleosidase Amn and pyrophosphate hydrolase PPase, and simultaneously realizes ATP cycle regeneration, AMP is recycled and converted into 5-phosphate ribose, and PPi is hydrolyzed.

[0009] The catalytic synthesis reaction process of the present invention is as follows: D-ribose and ATP are first synthesized into 5-phosphate ribose R-5-P under the action of ribokinase Rbk, and then react with ATP to generate ribophosphate pyrophosphate PRPP under the catalysis of ribophosphate pyrophosphate kinase Prs, and finally PRPP and nicotinamide NAM are reacted under the catalysis of nicotinamide phosphoribosyltransferase Nampt to obtain β-nicotinamide mononucleotide NMN;

[0010] In the presence of polyphosphate, the generated ADP is catalyzed by PPK2Ⅱ to regenerate ATP, thus realizing the cyclic regeneration of ATP. The byproduct AMP produced during the reaction is recovered by AMP nucleosidase and converted into 5-phosphate ribose R-5-P, which is then converted into phosphate ribose pyrophosphate PRPP. The byproduct pyrophosphate PPi is hydrolyzed by PPase to remove the effect of its accumulation on the reaction (the specific reaction formula is as follows: Figure 1 shown).

[0011] In the above technical scheme, further, the influence of by-products PPi and ADP on the yield during the catalytic synthesis reaction is effectively eliminated, AMP is recovered and converted into R-5-P, and then converted into PRPP, thereby increasing the synthesis pathway of PRPP without additional feed.

[0012] In the above technical solution, further, the ribokinase Rbk is derived from Escherichia coli, and the amino acid sequence of the ribokinase is shown in SEQ ID NO.1;

[0013] The phosphoribosyl pyrophosphate kinase Prs is derived from Escherichia coli, and the amino acid sequence of phosphoribosyl pyrophosphate kinase is shown in SEQ ID NO.2;

[0014] The nicotinamide phosphoribosyltransferase Nampt is derived from sulfur oomycetes, and the amino acid sequence of the nicotinamide phosphoribosyltransferase is shown in SEQ ID NO.3;

[0015] The polyphosphate kinase PPK2Ⅱ is derived from Sinorhizobium and is obtained from reported literature. The amino acid sequence of the polyphosphate kinase is shown in SEQ ID NO.4;

[0016] The AMP nucleosidase Amn is derived from Escherichia coli, and the amino acid sequence of the AMP nucleosidase is shown in SEQ ID NO.5;

[0017] The pyrophosphohydrolase PPase is derived from Escherichia coli, and the amino acid sequence of the pyrophosphohydrolase is shown in SEQ ID NO.6.

[0018] In the above technical solution, further, the catalytic synthesis reaction temperature is 20-50°C, preferably 37-40°C; the reaction pH is 6.5-8.5, preferably 7.5-8.0.

[0019] In the above technical solution, further, the catalytic synthesis reaction is carried out in PBS buffer or Tris-HCl buffer; preferably PBS buffer, and the buffer concentration is 40-60mM.

[0020] In the above technical solution, further, the molar ratio of D-ribose, ATP, polyphosphate and nicotinamide is 1:2-8:2-8:1-5, preferably 1:2-4:2-3:1-3, and the concentration of D-ribose is 1-10 mM.

[0021] In the above technical scheme, further, the molar ratio of the ribokinase Rbk to D-ribose is 1:2000-12000, preferably 1:6000, the molar ratio of phosphoribosyl pyrophosphokinase Prs to D-ribose is 1:1500-30000, preferably 1:6000, and the molar ratio of nicotinamide phosphoribosyltransferase Nampt to D-ribose is 1:150-4000, preferably 1:1500; the concentration of the polyphosphate kinase PPK2Ⅱ is 10-50 μM, preferably 25 μM, the concentration of the AMP nucleosidase Amn is 2-16 μM, preferably 9 μM, and the concentration of the pyrophosphohydrolase PPase is 0.25-2 μM, preferably 0.3 μM.

[0022] In the above technical solution, further, the coenzyme factor Mg is added to the reaction system 2+ , coenzyme factor Mg 2+ The concentration is 4-30 mM, preferably 8 mM.

[0023] In the above technical solution, further, Mg 2+ The source is one or a combination of two or more of magnesium chloride, magnesium sulfate, magnesium sulfite and magnesium nitrate.

[0024] In the above technical scheme, further, the ribokinase Rbk, ribose phosphoribosyl pyrophosphate kinase Prs, nicotinamide phosphoribosyl transferase Nampt, polyphosphate kinase PPK2Ⅱ, AMP nucleosidase Amn, and pyrophosphate hydrolase PPase are obtained by expressing recombinant microorganisms.

[0025] In the above technical scheme, further, the specific process of recombinant microbial expression is as follows: the genes encoding ribokinase Rbk, ribose pyrophosphate kinase Prs, nicotinamide phosphoribosyltransferase Nampt, polyphosphate kinase PPK2Ⅱ, AMP nucleosidase Amn, and pyrophosphate hydrolase PPase are cloned into recombinant expression vectors, introduced into host cells, induced for expression, and obtained by separation and purification.

[0026] In the above technical solution, further, the host is at least one of Escherichia coli, Bacillus subtilis and Saccharomyces cerevisiae, preferably Escherichia coli, and more preferably Escherichia coli BL21 (DE3).

[0027] In the above technical scheme, further, the recombinant expression vector is various conventional vectors in the art, selected from at least one of plasmid, cosmid, phage and viral vector, including pET-28a(+), cosmid vector, lambda phage vector, preferably the prokaryotic expression vector pET-28a(+).

[0028] In the above technical scheme, further, the specific forms of the ribokinase Rbk, ribose phosphoribosyl pyrophosphate kinase Prs, nicotinamide phosphoribosyl transferase Nampt, polyphosphate kinase PPK2Ⅱ, AMP nucleosidase Amn, and pyrophosphate hydrolase PPase include enzyme solution, enzyme lyophilized powder, enzyme-containing cells, immobilized enzymes and immobilized enzyme-containing cells, unpurified crude enzymes, or partially purified or completely purified enzymes, preferably purified enzyme solution.

[0029] Compared with the prior art, the present invention has the following beneficial effects:

[0030] The present invention constructs a method for synthesizing NMN with low enzyme consumption, which effectively reduces the proportion of enzyme consumption in production costs, and by introducing an ATP regeneration system, eliminates the inhibitory effect of ADP on Prs while realizing the recycling and regeneration of ATP. By introducing an AMP recovery system, the byproduct AMP in the system is converted again into 5-phosphate ribose R-5-P, and then converted into PRPP, thereby increasing the synthesis pathway of PRPP without additional feed. By introducing PPase, the effect of the byproduct PPi on the yield is eliminated, and ultimately the NMN yield is increased to more than 90%, achieving efficient synthesis of NMN under low-cost conditions. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 The present invention is a process flow chart of the enzymatic preparation of β-nicotinamide mononucleotide NMN. DETAILED DESCRIPTION

[0032] The present invention is further described below in conjunction with specific embodiments, but the present invention is not limited in any way.

[0033] Example 1 Construction of enzyme engineering strains

[0034] The amino acid sequences of ribokinase, phosphoribosyl pyrophosphokinase, nicotinamide phosphoribosyl transferase, polyphosphate kinase, AMP nucleosidase and pyrophosphohydrolase (the amino acid sequences are shown in SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4, SEQ ID NO.5 and SEQ ID NO.6, respectively) were sent to a gene synthesis company for E. coli codon optimization and artificial synthesis of coding genes, which were cloned into the NdeI and XhoI restriction sites of the prokaryotic expression vector pET-28a (+). The recombinant expression vectors containing the above genes were introduced into E. coli BL21 (DE3) by chemical transformation to obtain the corresponding enzyme gene expression engineering strains. The fermentation of the engineering strains used conventional LB fermentation medium, and the OD was first cultured at 37°C and 220rpm. 600 The p-value reached 0.6-0.8, and then isopropyl-β-D-thiogalactoside (IPTG) was used to induce expression, the bacteria were collected and resuspended and lysed with lysis buffer (50mM Tris-HCl, pH 8.0, 0.3M NaCl, 5mMβ-mercaptoethanol), and the supernatant was collected by centrifugation after lysis. The expressed recombinant protein was affinity adsorbed on a nickel ion affinity chromatography column pre-equilibrated with lysis buffer. After loading, 5 column volumes were washed with lysis buffer containing 10mM imidazole to remove impurities, and then the target protein was eluted with lysis buffer containing 300mM imidazole. The eluate was concentrated to 5 mL through an ultrafiltration tube and then loaded onto a gel filtration chromatography (Superdex 200, GE healthcare) pre-equilibrated with a purification buffer (50 mM Tris-HCl, pH 8.0, 0.3 M NaCl, 1 mM DTT, 5% glycerol) to further purify and remove high concentrations of imidazole. The concentrations of the respective proteins were determined by the Bradford method and then concentrated by ultrafiltration. Finally, ribokinase Rbk, phosphoribosyl pyrophosphate kinase Prs, nicotinamide phosphoribosyltransferase Nampt, polyphosphate kinase PPK2Ⅱ, AMP nucleosidase Amn and pyrophosphohydrolase PPase were obtained and stored in a -80°C refrigerator for later use.

[0035] Example 2 Preparation of NMN with Low Enzyme Consumption

[0036] Add 50mM PBS buffer solution, 2mM D-ribose, 10mM ATP, 2mM nicotinamide NAM, 12mM MgCl to the reaction system. 2, adjust the pH to 7.5-8.0, then add ribokinase Rbk at a final concentration of 10.8 mg / L, enzyme substrate ratio of 1:6000, final concentration of 11.4 mg / L ribose pyrophosphokinase Prs, enzyme substrate ratio of 1:6000, final concentration of 67.2 mg / L nicotinamide phosphoribosyltransferase Nampt, enzyme substrate ratio of 1:1500, control the reaction temperature at 40°C, maintain pH at 7.5-8.0, and react for 3 hours to obtain a crude product solution of β-nicotinamide mononucleotide. Detection by fluorescence method, take 100 μL of β-nicotinamide mononucleotide crude product solution, add 40 μL of dimethyl sulfoxide (DMSO) containing 20% ​​(v / v) acetophenone and 40 μL of 2M KOH. After incubation on ice for 2 minutes, 180 μL of 88% formic acid was added. After incubation at 37°C for 10 minutes, 200 μL of the mixed solution was placed in a black 96-well flat-bottom plate, and the fluorescence intensity was measured using a microplate reader (SpectraMax M2e). The excitation and emission wavelengths were set to 382 nm and 445 nm, respectively, and the NMN content was determined based on the fluorescence intensity; the yield was 20.9%, and the NMN output was 139.7 mg / L.

[0037] Example 3 Preparation of NMN with Low Enzyme Consumption (using PPase to hydrolyze PPi)

[0038] Add 50mM PBS buffer solution, 2mM D-ribose, 10mM ATP, 2mM nicotinamide NAM, 12mM MgCl to the reaction system. 2 , adjust the pH to 7.5-8.0, then add ribokinase Rbk with a final concentration of 10.8 mg / L, ribose pyrophosphokinase Prs with an enzyme-substrate ratio of 1:6000 and a final concentration of 11.4 mg / L, nicotinamide phosphoribosyltransferase Nampt with an enzyme-substrate ratio of 1:6000 and a final concentration of 67.2 mg / L, pyrophosphohydrolase PPase with an enzyme-substrate ratio of 1:1500 and a final concentration of 6.6 mg / L, control the reaction temperature at 40°C, maintain the pH at 7.5-8.0, and react for 3 hours to obtain a crude product solution of β-nicotinamide mononucleotide. The yield was tested to be 31.4%, and the NMN yield was 209.6 mg / L.

[0039] Example 4 Preparation of NMN with Low Enzyme Consumption (Introduction of ATP Cycle and AMP Recovery System)

[0040] Add 50mM PBS buffer solution, 2mM D-ribose, 5mM ATP, 2mM nicotinamide NAM, 8mM MgCl to the reaction system. 2, 5mM polyphosphate, adjust the pH to 7.5-8.0, then add ribokinase Rbk with a final concentration of 10.8mg / L, ribose pyrophosphokinase Prs with an enzyme-substrate ratio of 1:6000 and a final concentration of 11.4mg / L, nicotinamide phosphoribosyltransferase Nampt with an enzyme-substrate ratio of 1:6000 and a final concentration of 67.2mg / L, pyrophosphohydrolase PPase with an enzyme-substrate ratio of 1:1500 and a final concentration of 6.6mg / L, polyphosphate kinase PPK2Ⅱ with a final concentration of 890mg / L, and AMP nucleosidase Amn with a final concentration of 493.5mg / L, control the reaction temperature at 40°C, maintain the pH at 7.5-8.0, and react for 3h to obtain a crude product solution of β-nicotinamide mononucleotide. The yield was 95.7% and the NMN yield was 639.4mg / L.

[0041] Example 5 Preparation of NMN with Low Enzyme Consumption (Introduction of ATP Cycle and AMP Recovery System)

[0042] Add 50mM PBS buffer solution, 2mM D-ribose, 5mM ATP, 2mM nicotinamide NAM, 8mM MgCl to the reaction system. 2 , 2mM polyphosphate, adjust the pH to 7.5-8.0, then add ribokinase Rbk with a final concentration of 10.8mg / L, ribose pyrophosphokinase Prs with an enzyme-substrate ratio of 1:6000 and a final concentration of 11.4mg / L, nicotinamide phosphoribosyltransferase Nampt with an enzyme-substrate ratio of 1:6000 and a final concentration of 67.2mg / L, pyrophosphohydrolase PPase with an enzyme-substrate ratio of 1:1500 and a final concentration of 6.6mg / L, polyphosphate kinase PPK2Ⅱ with a final concentration of 890mg / L, and AMP nucleosidase Amn with a final concentration of 109.7mg / L, control the reaction temperature at 40°C, maintain the pH at 7.5-8.0, and react for 3h to obtain a crude product solution of β-nicotinamide mononucleotide. The yield was 98.6% and the NMN yield was 658.7mg / L.

[0043] Example 6 Preparation of NMN with Low Enzyme Consumption (Introduction of ATP Cycle and AMP Recovery System)

[0044] Add 50mM PBS buffer solution, 2mM D-ribose, 8mM ATP, 2mM nicotinamide NAM, 8mM MgCl to the reaction system. 2, 2mM polyphosphate, adjust the pH to 7.5-8.0, then add ribokinase Rbk with a final concentration of 10.8mg / L, enzyme-substrate ratio of 1:6000, final concentration of 11.4mg / L ribose pyrophosphokinase Prs, enzyme-substrate ratio of 1:6000, final concentration of 67.2mg / L nicotinamide phosphoribosyltransferase Nampt, enzyme-substrate ratio of 1:1500, final concentration of 6.6mg / L pyrophosphohydrolase PPase, final concentration of 890mg / L polyphosphate kinase PPK2Ⅱ, final concentration of 493.5mg / L AMP nucleosidase Amn, control the reaction temperature at 40°C, maintain pH at 7.5-8.0, and react for 3h to obtain a crude product solution of β-nicotinamide mononucleotide. The yield was 90.6% and the NMN yield was 605.3mg / L.

[0045] The present invention provides a method for preparing β-nicotinamide mononucleotide by an enzymatic method with low enzyme consumption, which significantly reduces the production cost. The yield influencing factors in the cascade reaction are eliminated by introducing an ATP regeneration system and a pyrophosphate hydrolase, while ATP can be recycled. The AMP recovery system is used to effectively utilize the by-product AMP in the system, thereby increasing the synthesis pathway of PRPP without additional feeding, and the final NMN yield can reach more than 90%.

[0046] For any technician familiar with the art, without departing from the scope of the technical solution of the present invention, the technical content disclosed above can be used to make many possible changes and modifications to the technical solution of the present invention, or modified into equivalent embodiments with equivalent changes. Therefore, any simple modification, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention should still fall within the scope of protection of the technical solution of the present invention.

Claims

1. A method for preparing β-nicotinamide mononucleotide by enzymatic method, characterized in that: The method uses polyphosphate, nicotinamide, D-ribose and ATP as substrates, and synthesizes β-nicotinamide mononucleotide NMN under the catalytic action of a multi-enzyme system including ribokinase Rbk, phosphoribosyl pyrophosphate kinase Prs, nicotinamide phosphoribosyltransferase Nampt, polyphosphate kinase PPK2Ⅱ, AMP nucleosidase Amn and pyrophosphate hydrolase PPase.

2. The method according to claim 1, characterized in that The amino acid sequence of the ribokinase Rbk is shown in SEQ ID NO.1; The amino acid sequence of the phosphoribosyl pyrophosphate stimulator Prs is shown in SEQ ID NO.2; The amino acid sequence of the nicotinamide phosphoribosyltransferase Nampt is shown in SEQ ID NO.3; The amino acid sequence of the polyphosphate kinase PPK2Ⅱ is shown in SEQ ID NO.4; The amino acid sequence of the AMP nucleosidase Amn is shown in SEQ ID NO.5; The amino acid sequence of the pyrophosphohydrolase PPase is shown in SEQ ID NO.

6.

3. The method according to claim 1, characterized in that The catalytic synthesis reaction temperature is 20-50°C, preferably 37-40°C; the reaction pH is 6.5-8.5, preferably 7.5-8.

0.

4. The method according to claim 1, characterized in that: The catalytic synthesis reaction is carried out in PBS buffer or Tris-HCl buffer; preferably PBS buffer, with a buffer concentration of 40-60 mM.

5. The method according to claim 1, characterized in that The molar ratio of D-ribose, ATP, polyphosphate and nicotinamide is 1:2-8:2-8:1-5, preferably 1:2-4:2-3:1-3, and the concentration of D-ribose is 1-10 mM.

6. The method according to claim 1, characterized in that The molar ratio of ribokinase Rbk to D-ribose is 1:2000-12000, preferably 1:6000, the molar ratio of phosphoribosyl pyrophosphokinase Prs to D-ribose is 1:1500-30000, preferably 1:6000, and the molar ratio of nicotinamide phosphoribosyltransferase Nampt to D-ribose is 1:150-4000, preferably 1:1500; the concentration of polyphosphate kinase PPK2Ⅱ is 10-50μM, preferably 25μM, the concentration of AMP nucleosidase Amn is 2-16μM, preferably 9μM, and the concentration of pyrophosphohydrolase PPase is 0.25-2μM, preferably 0.3μM.

7. The method according to claim 1, characterized in that Add coenzyme factor Mg to the reaction system 2+ , coenzyme factor Mg 2+ The concentration of Mg is 4-30mM, preferably 8mM; 2+ The source is one or a combination of two or more of magnesium chloride, magnesium sulfate, magnesium sulfite and magnesium nitrate.

8. The method according to claim 1, characterized in that The ribokinase Rbk, phosphoribosyl pyrophosphokinase Prs, nicotinamide phosphoribosyl transferase Nampt, polyphosphate kinase PPK2Ⅱ, AMP nucleosidase Amn, and pyrophosphohydrolase PPase are obtained by recombinant microbial expression. The specific process of recombinant microbial expression is as follows: the genes encoding the ribokinase Rbk, phosphoribosyl pyrophosphokinase Prs, nicotinamide phosphoribosyl transferase Nampt, polyphosphate kinase PPK2Ⅱ, AMP nucleosidase Amn, and pyrophosphohydrolase PPase are cloned into recombinant expression vectors, introduced into host cells, induced for expression, and separated and purified to obtain the genes.

9. The method according to claim 8, characterized in that The host is at least one of Escherichia coli, Bacillus subtilis and Saccharomyces cerevisiae, preferably Escherichia coli, and more preferably Escherichia coli BL21 (DE3); the recombinant expression vector includes pET-28a (+), a cosmid vector, and a λ phage vector, preferably pET-28a (+).

10. The method according to claim 1, characterized in that The specific forms of the ribokinase Rbk, phosphoribosyl pyrophosphate kinase Prs, nicotinamide phosphoribosyl transferase Nampt, polyphosphate kinase PPK2Ⅱ, AMP nucleosidase Amn, and pyrophosphate hydrolase PPase include enzyme solution, enzyme lyophilized powder, enzyme-containing cells, immobilized enzymes and immobilized enzyme-containing cells, unpurified crude enzymes, or partially purified or completely purified enzymes, preferably purified enzyme solution.

Citation Information

Patent Citations

  • Microorganisms having enhanced l-amino acids productivity and process for producing l-amino acids using the same

    CN105980545A

  • Method for preparing nicotinamide mononucleotide

    CN112159831A

  • Method for preparing beta-nicotinamide mononucleotide from biological enzyme

    CN115927513A

  • Method for preparing beta-nicotinamide mononucleotide through multienzyme catalysis

    CN118006527A

Cited By

  • Method for continuously preparing beta-nicotinamide mononucleotide

    CN122278973A